A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.
A Phase IIb Randomised Controlled Trial of the Safety, Immunogenicity and Efficacy of the Blood-stage Malaria Vaccine Candidates RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in Infants Aged 5-17 Months in Burkina Faso.
Sponsor: European and Developing Countries Clinical Trials Partnership (EDCTP)
A PHASE1/PHASE2 clinical study on Malaria,Falciparum, this trial is actively recruiting participants. The trial is conducted by European and Developing Countries Clinical Trials Partnership (EDCTP) and has accumulated 8 data snapshots since 2023. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Apr 2025 — Sep 2025 [monthly]
Recruiting PHASE1/PHASE2
Status: Unknown → Recruiting
-
Jan 2025 — Apr 2025 [monthly]
Unknown PHASE1/PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
▶ Show 3 earlier versions
-
Nov 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
May 2023 — Nov 2023 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2023 — May 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- European and Developing Countries Clinical Trials Partnership (EDCTP)
- Institut de Recherche en Sciences de la Sante, Burkina Faso
- University of Oxford
- Wellcome Trust
For direct contact, visit the study record on ClinicalTrials.gov .